Platform for Resting Immune Cell Gene Delivery

Back to search results

Genetically modified immune cells have extraordinary potential to be utilised in various immunotherapies (eg. HIV or refractory diseases, such as relapsed hematological malignancies). Gene delivery into resting immune cells is preferable given their superior capacity for engraftment, differentiation and effector functions. Whilst lentiviral vectors can act as delivery tools for resting cell types, dominant host-restrictions limit their capacity in resting immune cells. This project will be focussed on developing lentiviral platforms for resting immune cells using a system of viral evolution and viral gene bioprospecting. In tackling gene delivery, this project has the potential to transform future immunotherapeutic strategies.

Apply Now
Supervisory team

The Kirby Institute


Apply Now

Please start your application by taking the self assessment. Download the editable MS Word version or download the non-editable PDF version (best for Mac or mobile devices). Once the self assessment form is completed, save as a PDF and upload along with your application.

One file only.
50 MB limit.
Allowed types: gif jpg png bmp eps tif pict psd txt rtf html odf pdf doc docx ppt pptx xls xlsx xml avi mov mp3 ogg wav bz2 dmg gz jar rar sit svg tar zip.
If you have not done so, please complete the self assessment PDF as noted above.